



DT03 Rec'd PCT/PTO n 3 JAN 2005

PATENTS

Attorney Docket No. COLL/016

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

Applicants : Pines, et al.
Application No. : 10/500,690
Filed : June 30, 2004
For : QUINAZOLINONE COMPOUNDS IN COMBINED
MODALITIES FOR IMPROVED CANCER
TREATMENT
Group Art Unit : Not yet assigned
Examiner : Not yet assigned

New York, NY 10020
December 28, 2004

Hon. Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

**TRANSMITTAL LETTER FOR
INFORMATION DISCLOSURE STATEMENT**

Sir:

Transmitted herewith is an Information Disclosure Statement in the
above-identified application. This Statement is submitted:


☐ within three months of the application filing date;

☒ more than three months from the application filing date but

before the mailing date of the first Office Action on the merits.

In accordance with 37 C.F.R. § 1.97, submission of this Statement requires no fee. However, if for any reason a fee is due, the Director is hereby authorized to charge payment of any fees required in connection with this Information Disclosure Statement to Deposit Account No. 06-1075. A duplicate copy of this letter is transmitted herewith.

Respectfully submitted,




Jane T. Gurnison (Reg. No. 38,479)
Barbara A. Ruskin (Reg. No. 39,350)
Shilpi Banerjee (Reg. No. 53,965)
Attorneys for Applicants


FISH & NEAVE LLP
Customer No. 1473
1251 Avenue of the Americas
New York, New York 10020-1105
Tel.: (212) 596-9000
Fax: (212) 596-9090

I hereby certify that this
Correspondence is being
deposited with the U.S.
Postal Service as First
Class Mail in an envelope
Addressed to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450 on

December 28, 2004

Lillian Garcia


Signature of Person Signing



PATENTS
Attorney Docket No. COLL/016

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

Applicants : Pines, et al.
Application No. : 10/500,690
Filed : June 30, 2004
For : QUINAZOLINONE COMPOUNDS IN COMBINED
MODALITIES FOR IMPROVED CANCER
TREATMENT
Group Art Unit : Not yet assigned
Examiner : Not yet assigned

New York, NY 10020
December 28, 2004

Hon. Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicant hereby makes the following documents of record in the above-identified patent application:

U.S. PATENT DOCUMENTS

<u>Applicant(s)</u>	<u>Patent No.</u>	<u>Filing Date</u>
Waletzky, E., et al.	3,320,124	05/16/1967
Raether, W.	4,824,847	04/25/1989
Raether, W.	4,855,299	08/08/1989
Raether, W.	4,861,758	08/29/1989
Schildknecht, E.G., et al.	5,215,993	06/01/1993
Pines, M., et al.	5,449,678	09/12/1995
Nagler, A., et al.	5,891,879	04/06/1999
Pines, M., et al.	6,028,075	02/22/2000
Nagler, A., et al.	6,090,814	07/18/2000
Peterson, T.C.	6,294,350	09/25/2001

FOREIGN PATENT DOCUMENTS

COUNTRY	DOCUMENT NUMBER	DATE
PCT	WO 01/17531	15/03/2001
PCT	WO 00/09070	24/02/2000
PCT	WO 98/34613	13/08/1998

OTHER DOCUMENTS

Choi, E.T., et al., "Halofuginone, a specific collagen type I inhibitor, reduced anastomotic intimal hyperplasia," *Arch. Surg.* 130:257-261 (1995); Erratum in: *Arch. Surg.* 130:616 (1995)

Fata, F., et al., "Intra-abdominal fibrosis after systemic and intraperitoneal therapy containing fluoropyrimidines," *Cancer* 1;88: 2447-2451 (2000)

Nagler, A., et al. "Inhibition of glomerular mesangial cell proliferation and extracellular matrix deposition by halofuginone," *Kidney Int.* 52:1561-1569 (1997)


Wesseliùs, L., "Pulmonary complications of cancer therapy," *J. Compr. Ther.* 25:272-277 (1999)

Copies of the aforementioned documents, which are listed on the accompanying Form SB/08 (submitted in duplicate), are enclosed herewith.

It is respectfully requested that these documents be (1) fully considered by the Patent and Trademark Office during the examination of this application; and (2) printed on any patent which may issue on this application. Applicants request that a copy of Form SB/08, as considered and initialed by the Examiner, be returned with the next communication.

Consideration of the foregoing in relation to this patent application is respectfully requested.

Respectfully submitted,




Jane T. Gunnison (Reg. No. 38,479)
Barbara A. Ruskin (Reg. No. 39,350)
Shilpi Banerjee (Reg. No. 53,965)
Attorneys for Applicants

FISH & NEAVE LLP
Customer No. 1473
1251 Avenue of the Americas
New York, New York 10020-1105
Tel.: (212) 596-9000
Fax: (212) 596-9090

I hereby certify that this
Correspondence is being
deposited with the U.S.
Postal Service as First
Class Mail in an envelope
Addressed to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450 on

December 28, 2004

Lillian Garcia


Signature of Person Signing

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

of

Complete if Known

Application Number	10/500,690
Filing Date	June 30, 2004
First Named Inventor	Pines, et al.
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	COLL/016

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		us-3,320,124	05/16/1967	Waletzky, E., et al.	
		us-4,824,847	04/25/1989	Raether, W.	
		us-4,855,299	08/08/1989	Raether, W.	
		us-4,861,758	08/29/1989	Raether, W.	
		us-5,215,993	06/01/1993	Schildknecht, E.G., et al.	
		us-5,449,678	09/12/1995	Pines, M., et al.	
		us-5,891,879	04/06/1999	Nagler, A., et al.	
		us-6,028,075	02/22/2000	Pines, M., et al.	
		us-6,090,814	07/18/2000	Nagler, A., et al.	
		us-6,294,350	09/25/2001	Peterson, T.C.	
		us-6,420,371	07/16/2002	Pines, M. et al.	
		us-			
		us-			
		us-			
		us-			
		us-			
		us-			
		us-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		WO 01/17531	15/03/2001	Pines, M. et al.		
		WO 00/09070	24/02/2000	Pines, M. et al.		
		WO 98/34613	13/08/1998	Pines, M. et al.		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/500,690
Filing Date	June 30, 2004
First Named Inventor	Pines, et al.
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	COLL/016

Sheet

of

NON PATENT LITERATURE DOCUMENTSExaminer
Initials*Cite
No.¹

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

T²

CHOI, E.T., et al., "Halofuginone, a specific collagen type I inhibitor, reduced anastomotic intimal hyperplasia," Arch. Surg. 130:257-261 (1995); Erratum in: Arch. Surg. 130:616 (1995)

FATA, F., et al., "Intra-abdominal fibrosis after systemic and intraperitoneal therapy containing fluoropyrimidines," Cancer 1;88: 2447-2451 (2000)

NAGLER, A., et al. "Inhibition of glomerular mesangial cell proliferation and extracellular matrix deposition by halofuginone," Kidney Int. 52:1561-1569 (1997)

WESSELIUS, L., "Pulmonary complications of cancer therapy," J. Compr. Ther. 25:272-277 (1999)

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.